Telmisartan sodium salt pharmaceutical formulation
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
C07D-403/04
A61K-009/20
A61K-031/39
A61K-031/4184
출원번호
US-0825580
(2004-04-15)
등록번호
US-9029363
(2015-05-12)
우선권정보
DE-103 19 450 (2003-04-30)
발명자
/ 주소
Kohlrausch, Anja
출원인 / 주소
Boehringer Ingelheim International GmbH
대리인 / 주소
Morris, Michael P.
인용정보
피인용 횟수 :
0인용 특허 :
5
초록
The invention relates to a pharmaceutical formulation of the crystalline sodium salt of 4′-2-n-propyl-4-methyl-6-(1-methylbenzimidazol-2-yl)benzimidazol-1-ylmethylbiphenyl-2-carboxylic acid (telmisartan), and to processes for the preparation thereof.
대표청구항▼
1. A tablet or capsule comprising 30 to 90 mg of crystalline telmisartan sodium salt with a melting point of T=245° C.±5° C. and hydrochlorothiazide. 2. The tablet or capsule according to claim 1, further comprising one or more excipients selected from mannitol, sorbitol, xylitol, saccharose, calciu
1. A tablet or capsule comprising 30 to 90 mg of crystalline telmisartan sodium salt with a melting point of T=245° C.±5° C. and hydrochlorothiazide. 2. The tablet or capsule according to claim 1, further comprising one or more excipients selected from mannitol, sorbitol, xylitol, saccharose, calcium carbonate, calcium phosphate, lactose, croscarmellose sodium salt, crospovidone, sodium starch glycolate, hydroxypropylcellulose, maize starch, polyvinylpyrrolidone, copolymers of vinylpyrrolidone with other vinyl derivatives (copovidone), hydroxypropylcellulose, hydroxypropylmethylcellulose, microcrystalline cellulose or starch, magnesium stearate, sodium stearylfumarate, talc, hydroxypropylmethylcellulose, carboxymethylcellulose, cellulose acetate phthalate, polyvinyl acetate, water, water/ethanol, water/glycerol, water/sorbitol, water/polyethylene glycol, propylene glycol, cetyl stearyl alcohol, carboxymethylcellulose, and fatty substances, or suitable mixtures thereof. 3. The tablet or capsule according to claim 1, wherein the amount of the hydrochlorothiazide is 10 to 15 mg or 20 to 30 mg. 4. The tablet or capsule according to claim 3, wherein the amount of the hydrochlorothiazide is 12 to 13 mg or 24 to 26 mg. 5. A tablet or capsule comprising: (a) 30 to 90 mg of crystalline telmisartan sodium salt with a melting point of T=245° C.±5° C.;(b) hydrochlorothiazide; and(c) one or more excipients selected from sorbitol, xylitol, saccharose, croscarmellose sodium salt, crospovidone, sodium starch glycolate, hydroxypropylcellulose, polyvinylpyrrolidone, copolymers of vinylpyrrolidone with other vinyl derivatives (copovidone), hydroxypropylcellulose, hydroxypropylmethylcellulose, microcrystalline cellulose, sodium stearylfumarate, hydroxypropylmethylcellulose, water, water/ethanol, water/glycerol, water/sorbitol, water/polyethyleneglycol, propyleneglycol, cetyl stearyl alcohol, carboxymethylcellulose, and fatty substances, or suitable mixtures thereof. 6. The tablet or capsule according to claim 5, wherein the amount of the hydrochlorothiazide is 10 mg to 15 mg or 20 mg to 30 mg. 7. The tablet or capsule according to claim 6, wherein the amount of the hydrochlorothiazide is 12 mg to 13 mg or 24 mg to 26 mg. 8. The tablet or capsule according to one of claims 1, 2, 3, 4, 5, 6, and 7, wherein the amount of the crystalline telmisartan sodium salt is 60 mg to 90 mg. 9. The tablet or capsule according to claim 8, wherein the amount of the crystalline telmisartan sodium salt is 80 mg to 85 mg. 10. The tablet or capsule according to one of claims 1, 2, 3, 4, 5, 6, and 7, wherein the amount of the crystalline telmisartan sodium salt is 30 mg to 60 mg. 11. The tablet or capsule according to claim 10, wherein the amount of the crystalline telmisartan sodium salt is 40 mg to 45 mg. 12. A tablet or capsule comprising a crystalline telmisartan sodium salt with a melting point of T=245° C.±5° C., hydrochlorothiazide, sorbitol, and magnesium stearate, compressed directly into tablets. 13. A tablet or capsule comprising: (a) compressed dry granules comprising 30 to 90 mg of crystalline telmisartan sodium salt with a melting point of T=245° C.±5° C., mannitol, magnesium stearate, and hydroxypropylcellulose; and(b) a mixture of hydrochlorothiazide, mannitol, microcrystalline cellulose, and sodium glycol starch. 14. A tablet or capsule comprising: (a) 30 to 90 mg of crystalline telmisartan sodium salt with a melting point of T=245° C.±5° C.; and(b) one or more excipients selected from sorbitol, xylitol, saccharose, croscarmellose sodium salt, crospovidone, sodium starch glycolate, copolymers of vinylpyrrolidone with other vinyl derivatives (copovidone), hydroxypropylcellulose, hydroxypropylmethylcellulose, sodium stearylfumarate, hydroxypropylmethylcellulose, water, water/ethanol, water/glycerol, water/sorbitol, water/polyethyleneglycol, propyleneglycol, cetyl stearyl alcohol, carboxymethylcellulose, and fatty substances, or suitable mixtures thereof.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (5)
Hauel Norbert (Schemmerhofen DEX) Narr ; deceased Berthold (late of Biberach DEX by Elisabeth Narr ; legal representative ) Ries Uwe (Biberch DEX) van Meel Jacobus C. A. (Mittelbiberach DEX) Wienen W, Benzimidazoles useful as angiotensin-11 antagonists.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.